Replies to post #213161 on Biotech Values

[biomaven0]

Thanks for the perspective. Hadn't thought of this from a "race to market" perspective.

For true long-term efficacy you have to hit cancer stem cells and/or block mets. That pretty much requires OS as an endpoint.